GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2023-03-09| Trials & Approvals

Mesoblast’s Resubmission Brings First-of-its-Kind Therapy One Step Closer to Approval

by Joy Lin
Share To
Concept word 'FDA' on cubes on a beautiful wooden table. White background. Business concept. Copy space.

The US FDA has accepted Mesoblast’s Biologics License Application (BLA) resubmission for remestemcel-L in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD), a life-threatening complication of an allogeneic bone marrow transplant for blood cancer. The regulatory review is expected to be completed on August 2, 2023. 

The acceptance is a relief for New York-based Mesoblast, after the company was hit with a complete response letter for remestemcel-L in October 2020. The FDA recommended then that Mesoblast conduct an extra study to provide further evidence of the effectiveness of the cell therapy. 

“Over the last two years we have worked tirelessly to address the issues previously raised by FDA. We look forward to working closely with the Agency over the review period with the aim to make remestemcel-L available as a therapy for children suffering from SR-aGVHD,” said Mesoblast CEO Silviu Itescu.

If approved, Remestemcel-L could become the first off-the-shelf cell-based medicine in the US, and the first therapy for children under 12 years of age with SR-aGVHD. The therapy holds designations for Fast Track and Priority Review, which could speed up the regulatory process. 

Related Article: Praxis Stock Hits All-Time Low After Phase 2 Tremor Data Released

Remestemce-L Associated with Positive Responses and Survival

Remestemcel-L contains culture-expanded mesenchymal stromal cells derived from the bone marrow of an unrelated donor. Administered intravenously, the therapy may help counteract the inflammation in SR-aGVHD by down-regulating the production of pro-inflammatory cytokines, increasing the production of anti-inflammatory cytokines, and enabling the recruitment of anti-inflammatory cells.

Mesoblast’s original filing included data from three trials showing consistent treatment responses and survival with remestemcel-L treatment. 

The resubmission adds more clinical and biomarker data, including from a study of children with high-risk disease. The study showed that 67% of high-risk children treated with remestemcel-L responded positively to treatment and were alive after 180 days compared to 10% of children treated with various biologics such as ruxolitinib. 

Additionally, a four-year survival study performed by the Center for International Blood and Marrow Transplant Research (CIBMTR) showed that 63% of children treated with remestemcel-L survived at one year while 51% survived at two years. The results compared to an expected two-year survival rate of 25-38% using the best available therapy. 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Major Win – FDA Grants Fast Track Designation to Adicet Bio’s ADI-001 for Lupus Disease
2025-02-07
Easing the Mental Health Burden: How MDMA, Psilocybin, and Other Psychedelics May Open Doors for Treating PTSD, Addiction, and Autism
2025-01-28
Drug Promotion, Nonprescription Pathways, and Advanced Manufacturing: FDA’s Key Focus Areas in 2024 and What’s Next for 2025
2025-01-23
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top